Resources for The Millennium Alliance Virtual Assembly Attendees

Many people are surprised to learn that DNA can affect whether hundreds of medications work (or not) for any given individual and if they are safe to take (or likely to cause potentially dangerous adverse drug events). That’s because natural variation in our genetic code can cause the same drug to produce different effects on different people. Both employers and employees bear the burden of trial-and-error prescribing, which includes wasted resources, time, and poor health.

Coriell Life Sciences’ Corigen^® Medication Safety Program uses a simple DNA test to provide participants and their doctors clinically relevant insight on which medications are likely to be ineffective or unsafe — as well as those that are safest and most effective — for them based on their DNA and dozens of other important factors. Corigen is the most comprehensive medication safety solution on the market.

The results include:

• Safer, more effective treatment plans
• Measurable improvements in employee health
• Significant economic savings (See case study on how one of our clients reduced direct medical charges by $37+ million in 32 months)

With the input of the sponsoring organization, CLS handles everything from population analytics to member engagement and enrollment, test results delivery, and detailed reporting.

Resources

About Coriell Life Sciences

Coriell Life Sciences (CLS), an international leader in precision medicine, delivers DNA testing benefits that empower the most precise medical care, improve population health, and reduce healthcare costs.

The organization is the commercial spin-out of the world-renowned Coriell Institute for Medical Research, a non-profit biomedical research institution, founded in 1953, dedicated to studying the human genome. In 2007, the Institute launched the Coriell Personalized Medicine Collaborative (CPMC), a research study seeking to understand the value of personalized medicine and pharmacogenomics (the science of how an individual’s DNA impacts their response to medication) in clinical decision-making and healthcare management. The results of that study led to the founding of CLS in 2013.

Today, CLS works with large employers, public and private payer organizations, pharmacy benefit managers, benefits brokers, healthcare systems, academic institutions, and laboratories around the globe to eliminate the needless risks, costs, and waste associated with trial-and-error prescribing.

In recognition of its innovative solutions, CLS has been named IBM’s Global Entrepreneur of the Year, MedTech Breakthrough’s Best Overall Genomics Company and Best Overall Genomics Solution, and a Top Precision Medicine Solution Provider in Europe by Healthcare Tech Outlook. In addition to earning a spot on the Inc. 5000, CLS has also received the Employer Health Innovation Roundtable Traction Award and the Pharmacy Benefit Management Institute’s Excellence Award for Cost Containment.